Skip to content


You currently have no items in your basket.


Cellcolabs is a biotech impact start-up specializing in industrial GMP production of high quality stem cells (mesenchymal stromal cells) in order to make them available at scale. Their ultimate goal is to accelerate stem cell research and make the treatments of the future available for all.

View All Cellcolabs Products

Katarina Le Blanc
Total number of peer-reviewed scientific papers: 132
Total number of review articles and book chapters: 67
The total amount of citations as of August 26, 2022: 33 740

Selected Publications

1.            Le Blanc K, Tammik C, Sundberg B, Haynesworth S, Ringdén O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand J Immunol 2003; 57; 11-20. Cited 1 028 times.

2.            Le Blanc K, Tammik L, Zetterberg E, Rosendahl K, Ringdén O. HLA-expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp Hematol, 2003; 31: 890-896. Cited 1 228 times.

3.            Le Blanc K, Rasmusson I, Sundberg B, Götherström C, Uzunel M, Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet, 2004; 363: 1439-1441. Cited 2 051 times.

4.            Le Blanc K, Frassoni F, Ball L, Locatelli F, Roelofs H, Lewis I, Lanino E, Sundberg B, Bernardo ME, Remberger M, Dini G, Egeler M, Bacigalupo A, Fibbe W, Ringdén O. Mesenchymal stem cells for treatment of steroid-resistant, severe, acute graft-versus-host disease: a phase II study. Lancet. 2008; 371: 1579-1586. Cited 1980 times.

5.            M Dominici, K Le Blanc, I Mueller, I Slaper-Cortenbach, Fc Marini, Ds Krause, Rj Deans, A Keating, Dj Prockop & Em Horwitz (2006) Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement, Cytotherapy, 8:4, 315-317 Cited 19430 times.